1,1-Dimethyl-2-(2-(4-morpholinophenyl))guanidine monofumarate | 161748-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1,1-Dimethyl-2-(2-(4-morpholinophenyl))guanidine monofumarate
• 英文别名: (E)-but-2-enedioic acid;1,1-dimethyl-2-(2-morpholin-4-ylphenyl)guanidine
• CAS: 161748-40-9
• 化学式: C17H24N4O5
• 分子量: 364.4
• InChiKey: FFEKJBVVAJTQST-WLHGVMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.74
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N,N-二甲基硫脲 、 4-2-胺苯基吗啉 生成 1,1-Dimethyl-2-(2-(4-morpholinophenyl))guanidine monofumarate
  参考文献：
  名称：

  Phenylamidine and phenylguanidine derivatives and their use as

  摘要：

  公式为I ## STR1 ## 的化合物及其盐，其中n = 0或1，R.sub.1和R.sub.2分别为脂肪族或环烷基或NR.sub.1 R.sub.2是一个可选取代的杂环环，R.sub.3是烷基，环烷基或可选取代的氨基，R.sub.5是一个脂肪基，R.sub.6是H，一个可选取代的脂肪基或环烷基，或R.sub.3和R.sub.5与它们附着的氮和碳原子形成一个可选取代的杂环环，或R.sub.5和R.sub.6与它们附着的氮原子形成一个可选取代的杂环环，可由选用的烷基取代或R.sub.7是可选取代的烷基，烷氧基，烷基硫，烷基亚砜，烷基磺酰，烷氧羰基，三氟甲基或氰基，具有作为降血糖剂的用途。

  公开号：

  US05373008A1

文献信息

• Phenylamidine and phenylguanidine derivatives and their use as
  申请人：The Boots Compant plc.

  公开号：US05373008A1

  公开（公告）日：1994-12-13

  Compounds of formula I ##STR1## and their salts in which n=0 or 1, R.sub.1 and R.sub.2 are each aliphatic or cycloalkyl or NR.sub.1 R.sub.2 is an optionally substituted heterocyclic ring, R.sub.3 is alkyl, cycloalkyl or optionally substituted amino, R.sub.5 is an aliphatic group, R.sub.6 is H, an optionally substituted aliphatic group or a cycloalkyl group, or R.sub.3 and R.sub.5 together with the nitrogen and carbon atoms to which they are attached form an optionally substituted heterocyclic ring or R.sub.5 and R.sub.6 together with the nitrogen to which they are attached form a heterocyclic ring optionally substituted by alkyl and R.sub.7 is optionally substituted alkyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkoxycarbonyl, trifluoromethyl or cyano have utility as hypoglycemic agents.

  公式为I ## STR1 ## 的化合物及其盐，其中n = 0或1，R.sub.1和R.sub.2分别为脂肪族或环烷基或NR.sub.1 R.sub.2是一个可选取代的杂环环，R.sub.3是烷基，环烷基或可选取代的氨基，R.sub.5是一个脂肪基，R.sub.6是H，一个可选取代的脂肪基或环烷基，或R.sub.3和R.sub.5与它们附着的氮和碳原子形成一个可选取代的杂环环，或R.sub.5和R.sub.6与它们附着的氮原子形成一个可选取代的杂环环，可由选用的烷基取代或R.sub.7是可选取代的烷基，烷氧基，烷基硫，烷基亚砜，烷基磺酰，烷氧羰基，三氟甲基或氰基，具有作为降血糖剂的用途。
• Compositions and methods for regulating pancreatic beta cell function using adipsin
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10328131B2

  公开（公告）日：2019-06-25

  The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.

  本发明提供了通过调节阿地普酶活性和/或表达调节胰腺β细胞功能的组合物和方法。本发明还提供了通过调节或检测腺苷酸活性和/或表达预防、治疗、诊断和预后代谢紊乱（如糖尿病）的方法。
• OBG3 globular head and uses thereof for decreasing body mass
  申请人：——

  公开号：US20020037849A1

  公开（公告）日：2002-03-28

  The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

  本发明涉及肥胖症研究领域。肥胖症是一个严重而普遍的公共健康问题。现已发现一种化合物，即球状 OBG3，可减少动物的体重增加。该化合物可有效降低体重，治疗与肥胖有关的疾病和失调。这些与肥胖有关的疾病包括高脂血症、动脉粥样硬化、糖尿病和高血压。
• Use of adipsin/complement factor D in the treatment of metabolic related disorders
  申请人：GENSET, S.A.

  公开号：US20030092620A1

  公开（公告）日：2003-05-15

  The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. Adipsin polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, insulin resistance, diabetes, and hypertension.

  本发明涉及代谢研究领域。代谢紊乱，如肥胖，是一个严重而普遍的公共健康问题。已发现的 Adipsin 多肽被认为有利于治疗代谢紊乱。这些化合物应能有效降低体重，治疗与代谢相关的疾病和紊乱。这些与新陈代谢有关的疾病和紊乱包括高脂血症、动脉粥样硬化、胰岛素抵抗、糖尿病和高血压。
• Medical treatment
  申请人：——

  公开号：US20040077730A1

  公开（公告）日：2004-04-22

  A compound of formula I 1 or a pharmaceutically acceptable salt thereof in which R 1 and R 2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.

  式 I 的化合物 1 或其药学上可接受的盐，其中 R 1 和 R 2 1或其药物可接受盐，其中 R 1 和 R 2 独立地为 H 或甲基（例如 N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐，可选择以其一水合物的形式）用于减轻葡萄糖耐受性受损和非胰岛素依赖型糖尿病患者的胰岛素抵抗。